The AJMC® Leukemia & Lymphoma compendium is a comprehensive resource for clinical news and expert insights for the blood cancers and their treatments.
Modern Therapies, Younger Age Predict Improved Outcomes in Waldenström Macroglobulinemia
Patients who are diagnosed with Waldenström macroglobulinemia (WM) at age 55 or younger tend to have low risk profiles and very high overall survival rates.
Levofloxacin Prophylaxis Shown to Be Cost-effective in Pediatric ALL, AML
Children receiving intensive chemotherapy benefit from prophylaxis with levofloxacin to an extent that would justify the cost of the drug, a new analysis finds.
Researchers Leverage p53 Expression to Identify TP53 Missense Mutations in MCL
Reporting on their findings in the British Journal of Haematology, researchers have used immunohistochemistry (IHC) to leverage p53 expression as an identifier of mantle cell lymphoma (MCL) patients carrying mutations in tumor protein p53 (TP53), an indicator of poor prognosis in the disease.
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
Fewer off-target effects mean second-generation BTK inhibitors offer less cardiotoxicity and allow patients to stay on them longer, increasing their efficacy.
TML Helps Predict Time to Treatment in CLL and Its Precursor, Study Shows
Patients with chronic lymphocytic leukemia (CLL) often face months or years of uncertainty. A new study might help those patients better understand their progression timeline.
Study Explores Causes of Bleeding in Patients with CLL, MCL Taking Ibrutinib
A significant proportion of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) experience bleeding when taking ibrutinib—a recent study probes why.
Novartis Says Tisagenlecleucel Met CRR in Early FL Data
Tisagenlecleucel, sold as Kymriah by Novartis, met its primary end point of complete response rate (CRR) in an interim analysis of a phase 2 study for relapsed or refractory follicular lymphoma (FL).
In Assessing CLL HRQoL, Type of Questionnaire Matters, Study Says
Understanding the patient point of view can help with treatment decisions as well as gauge the impact of treatment, the authors said.
Immunoglobulin Abnormalities Do Not Affect Overall Survival in CLL, Study Finds
While immunoglobulin abnormalities appear to shorten treatment-free survival periods, they do not have an impact on overall survival in patients with chronic lymphocytic leukemia (CLL).
FDA Approves CAR T-Cell Therapy for Adults With R/R Mantle Cell Lymphoma
The therapy, to be sold as Tecartus, will be used to treat adult patients with mantle cell lymphoma who have relapsed or not responded to other treatments.
CLL Experts Favor Social Distancing, but Vary on Treatment Continuation Amid Pandemic
Experts surveyed regarding how best to treat patients with chronic lymphocytic leukemia (CLL) amid the pandemic agreed with social distancing, but were cautious about universal testing and treatment continuation.
Age, Recent Treatment Appear to Influence Severity of COVID-19 in Patients With CLL
Older patients with chronic lymphocytic leukemia (CLL) appear to be more likely to have severe symptoms if they contract coronavirus disease 2019, according to new research.
Leukemia Rates Falling, but AML, CLL Are Exceptions
A new analysis of nearly 3 decades of data suggests leukemia rates are falling, except for 2 specific types.
FDA Lifts Partial Hold for Phase 2 Trial of R/R Hodgkin Lymphoma Therapy
FDA has lifted a partial clinical hold on a phase 2 trial of a treatment for patients with relapsed or refractory (R/R) Hodgkin lymphoma from ADC Therapeutics. The trial of camidanlumab tesirine (Cami), an antibody drug conjugate that binds to CD25, is evaluating the safety and efficacy of the therapy and is intended to support the submission of a Biologics License Application to the FDA.
NCCN Patient Guidelines Highlight Side Effects of Immunotherapy, CAR T-Cell Therapy
Immunotherapy and chimeric antigen receptor (CAR) T-cell therapy are new and important treatments revolutionizing care of some cancers; however, their side effects can be very different than what is seen in traditional approaches, such as chemotherapy.
Rituximab Regimen Improves Survival in Children With Aggressive B-Cell Lymphoma
Treating children with aggressive B-cell lymphoma with rituximab can improve cure rates to up to 95%.
COVID-19 Raises Difficult Challenges for CAR T-Cell Therapy Administration
Patients with B-cell non-Hodgkin lymphomas and B-cell acute lymphoblastic leukemia can benefit greatly from chimeric antigen receptor (CAR) T-cell therapy, but providing that therapy has become much more difficult in the age of coronavirus disease 2019 (COVID-19).
Selinexor Approved Under Accelerated Pathway to Treat DLBCL
The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The oral treatment is to be used after at least 2 lines of systemic therapy.
Rituximab, Anthracycline Have Benefits in Oldest Patients With Diffuse Large B-Cell Lymphoma
Most studies of patients with diffuse large B-cell lymphoma do not include those over the age of 80. However, a new study says those patients, like younger patients, benefit from receiving rituximab and anthracycline in their chemotherapy regimens when possible.
Newly Identified MicroRNA Signatures Could Reshape Pediatric ALL Diagnosis, Study Says
Diagnosis pediatric acute lymphoblastic leukemia (ALL) can be a costly and cumbersome experience. New research has identified microRNA signatures that could simplify the process of diagnosis and classifying the cancer.
CAG Regimen Shows Strong Results as Salvage Therapy in T-ALL
Patients with relapsed/refractory T-cell lymphoblastic leukemia face poor outcomes, and are generally treated by salvage therapy followed by allogeneic hematopoietic stem cell transplant. A new study suggests an optimal option for salvage therapy.
Review Finds Questions Remaining About Ibrutinib Dose Modification in CLL
A subset of patients taking ibrutinib as a therapy for chronic lymphocytic leukemia (CLL) will require dose modifications. A new study attempts to evaluate the impacts of such changes, though the authors find many questions remain unsolved.
New Tool Aims for Accurate Risk Assessment in AML, Even With Gaps in Data
Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty care center.
Biomarker Advances Bring New Hope of Targeted PTCL Therapy
Peripheral T-cell lymphoma (PTCL) has been a challenging nemesis for scientists, in large part because it is a widely heterogeneous disease. However, new research into biomarkers for the cancer may lead to better therapies soon.
Zanubrutinib Shows High Response Rates in Single-Arm Phase 2 Study
The bruton tyrosine kinase inhibitor zanubrutinib was shown to generate high response rates in a new study of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Cellular Metabolism a Potential Target for New AML Therapies
Five metabolic inhibitors appear to have strong antiproliferative effects on acute myeloid leukemia (AML), according to a new study.
Case Study Highlights Potential Link Between TKIs and Lymphoplasmacytic Lymphoma
Patients who are treated with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia are at a higher risk of a secondary malignancy. A new case study suggest the list of potential secondary malignancies should include lymphoplasmacytic lymphoma.
Nivolumab-Based First-Line Treatment Is Effective in Treating Hodgkin Lymphoma, Study Finds
Nivolumab-based first-line treatment is highly effective in patients with early-stage unfavorable classic Hodgkin lymphoma, according to results from the Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma trial published in JAMA Oncology.
Study Explains Differential Diagnosis of CLL/SLL From Other Lymphomas
Chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL) is rare, making it difficult to differentiate from other types of lymphoma. A new study helps explain key unique traits.
2 Types of Rituximab Combinations Effective in Transplant-Eligible Patients With Mantle Cell Lymphoma
A new pooled analysis of rituximab/bendamustine and rituximab/cytarabine in transplant-eligible patients with mantle cell lymphoma (MCL) finds it leads to durable positive results in most patients.
2 Clarke Drive Cranbury, NJ 08512